Company: NCEL
Filing Date: 2025-01-08
Form Type: 425
Source: 0001213900-25-001822
Chunk: 3

Company: NewcelX Ltd.
Filing Date: 2025-01-08
Form: 425
Chunk 3
---

cure patients with insulin-dependent diabetes. Kadimastem was founded by Professor Michel Revel, Chief Scientific Officer of Kadimastem
and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention
and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange
(TASE: KDST).

Safe Harbor Statement

This press release contains expressed or implied
forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS and Kadimastem are using forward-looking statements
when they discuss the expected closing of the transaction and the potential benefits of the transaction to NLS and Kadimastem and their
respective shareholders, as well as the expected strategic position of the combined company following the merger, if completed. These
forward-looking statements and their implications are based on the current expectations of the management of NLS and Kadimastem and are
subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking
statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking
statements: risks related to the companies’ ability to complete the merger on the proposed terms and schedule, including risks and
uncertainties related to the satisfaction of the closing conditions related to the merger agreement and risks and uncertainties related
to the failure to timely, or at all, obtain shareholder approvals for the transaction; unexpected costs, charges or expenses resulting
from the transaction and potential adverse reactions or changes to business relationships resulting from the announcement or completion
of the proposed merger; changes in technology and market requirements; either or both companies may encounter delays or obstacles in launching
and/or successfully completing their clinical trials; the companies’ products may not be approved by regulatory agencies; their
technologies may not be validated as they progress and their methods may not be accepted by the scientific community; either of both of
the companies may be unable to retain or attract key employees whose knowledge is essential to the development of their products; unforeseen
scientific difficulties may develop with the products being advanced by the companies; their products may wind up being more expensive
than anticipated; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical
studies may not correlate with the results of human clinical trials; the companies’ patents may not be sufficient; their products
may